1. A pharmaceutical composition for treating benign prostatic hyperplasia, comprising from 4 mg to 79 mg of degarelix or a pharmaceutically acceptable salt thereof and a solvent, wherein the concentration of degarelix or its salt in the solvent is from 5 to 80 mg / ml. The pharmaceutical composition according to claim 1, wherein the concentration of degarelix or its salt in the solvent is from 35 to 45 mg / ml. The pharmaceutical composition according to claim 1, containing from 9 to 33 mg of degarelix or a pharmaceutically acceptable salt thereof. The pharmaceutical composition according to claim 1, containing from 10 to 30 mg of degarelix or a pharmaceutically acceptable salt thereof. The pharmaceutical composition according to claim 1, wherein the solvent is water. The pharmaceutical composition according to claim 1, wherein the concentration of degarelix (or its salt) in the solvent is 40 mg / ml. A pharmaceutical preparation containing from 4 mg to 79 mg of degarelix or its pharmaceutically acceptable salt and a solvent, wherein the concentration of degarelix or its salt in the solvent is from 5 to 80 mg / ml. 8. The drug according to claim 7, where the concentration of degarelix or its salt in the solvent is from 35 to 45 mg / ml. The drug according to claim 7, containing from 9 to 33 mg of degarelix or its pharmaceutically acceptable salt. The drug according to claim 7, containing from 10 to 30 mg of degarelix or its pharmaceutically acceptable salt. A composition or preparation according to any one of claims 1 to 10, further comprising an excipient. 12. The composition or preparation of claim 11, wherein the degarelix or a salt thereof is a combined lyophilisate with an excipient. The composition or preparation of claim 11, wherein the excipient is mannitol. The preparation according to claim 7, wherein the solvent is water. P�1. Фармацевтическая композиция для лечения доброкачественной гиперплазии простаты, содержащая от 4 мг до 79 мг дегареликса или его фа
